A Phase 2, Open-Label, Single-Arm, Sequential-Panel Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Posaconazole (POS, MK-5592) Intravenous and Powder for Oral Suspension Formulations in Pediatric Participants From Birth to Less Than 2 Years of Age With Possible, Probable, or Proven Invasive Fungal Infection
Latest Information Update: 29 Sep 2025
At a glance
- Drugs Posaconazole (Primary) ; Posaconazole (Primary)
- Indications Mycoses
- Focus Pharmacokinetics
- Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.
Most Recent Events
- 27 Aug 2025 Planned End Date changed from 31 Dec 2025 to 31 Dec 2026.
- 27 Aug 2025 Planned primary completion date changed from 16 Dec 2025 to 16 Dec 2026.
- 13 Jun 2023 Planned End Date changed from 31 Dec 2024 to 31 Dec 2025.